IFFO2

Across TCGA pan-cancer cohorts, IFFO2 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of IFFO2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where IFFO2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types IFFO2 is over-expressed in tumor, although a few such as KICH and BRCA show the opposite, repressed pattern.

KIRC, LIHC, and KICH are the cancer types where IFFO2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IFFO2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+0.794	<.001	10	view →
LIHC	Female	II,III,IV	+1.380	<.001	9	view →
KICH	Female	All	−1.696	<.001	8	view →
BRCA	All	III,IV	−1.840	<.001	6	view →
BLCA	All	All	−0.917	.006	6	view →
STAD	All	All	+0.866	.030	6	view →
LUSC	Male	All	+0.864	<.001	6	view →
COAD	Female	All	+0.841	<.001	6	view →
THCA	All	III,IV	+0.652	.002	6	view →
CHOL	All	All	+2.603	<.001	5	view →
READ	All	All	+1.214	.003	5	view →
UCEC	All	All	−0.599	.026	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

IFFO2–KIRC

Open the KIRC breakdown →